Since the
mid 1970’s, there has been a bacteria evolving from ‘nuisance status’ to a
serious public health concern. This bacterium is known as methicillin-resistant
Staphylococcus aureus, or MRSA. Statistically, about one-third of the world’s
population carries the S. aureus bacteria on their bodies, primarily in the
nose and on the skin. The bacterium is often present without there being any
signs of outward infection. According to the Centers for Disease Control and
Prevention (CDC), of the people with S. aureus present, about 1 percent has
MRSA.
HA-MRSA is
contracted in hospital or healthcare settings and is one of many
hospital-acquired infections showing an increase in antimicrobial resistance.
Increasing in numbers over the last decade, the trend appears to be due to a
number of factors including an increased number of immunocompromised and
elderly patients, an increase in invasive procedures and failures in effective
infection control habits such as washing one’s hands before contact and removal
of non-essential catheters.
CA-MRSA is
caused by emerging strains unlike those responsible for HA-MRSA. These strains
can cause infections in healthy people with no contact or connections to
healthcare environments. CA-MRSA infections are known to occur as soft tissue
infections, but can develop into more invasive, life-threatening infections.
CA-MRSA is trending upward in the US and worldwide, and it tends to occur in
conditions where there is close contact with another person. Wrestlers,
football players, people kept in close quarters such as soldiers, inmates,
childcare workers, and residents of long-term care facilities are particularly
vulnerable.
MRSA has
attracted the attention of the medical research community, illustrating the
urgent need to develop better ways to diagnose and treat bacterial infections.
One such company at the forefront of early diagnosis is Zenosense.
ZENO’s
mission is to develop effective medical devices targeting the early detection
of both deadly bacteria and certain cancers, and then market and sell these
products to hospitals and primary healthcare facilities. Two devices are
currently under development – a device intended to detect the
Methicillin-resistant Staphylococcus aureus “Super-Bug” (MRSA) and a device
intended to detect Lung Cancer. The device intended to detect lung cancer is
currently being tested and is said to be showing good sensitivity. Using a
common Electronic Nose technology platform, the devices analyze Volatile
Organic Compounds (VOCs) which are present in the exhaled breath of patients,
scanning for certain biomarkers which can identify the presence of infection.
Find more
information on the company, visit www.zenosense.net
About QualityStocks
QualityStocks
is committed to connecting subscribers with companies that have huge potential
to succeed in the short and long-term future. We offer several ways for
investors to find, evaluate, and learn more about investing in these companies.
Sign up
for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The
Quality Stocks Daily Blog http://blog.qualitystocks.net
The
Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The
Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
No comments:
Post a Comment